Skip to main content
ZYBT
NASDAQ Life Sciences

Zhengye H1 2026: Revenue Falls 18%, Going-Concern Doubt Disclosed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.5
Mkt Cap
$44.587M
52W Low
$0.616
52W High
$8.01
52W Position info
144% above low
Off High info
81% below high
Rel. Volume
Market data snapshot near publication time

ZYBT has more than doubled off its 52-week low of $0.616.

Summary

Zhengye Biotechnology's H1 2026 revenue fell 18.3% to RMB50.9 million (US$7.5 million) with a RMB22.2 million (US$3.3 million) net loss, and the filing discloses going-concern doubt that management plans to address by rolling over short-term bank loans.


Key Events · Earnings and Guidance · ZYBT

  • H1 2026 Revenue Down 18.3%

    Revenue fell to RMB50,947 thousand (US$7,509 thousand) from RMB62,328 thousand, driven by customer cost-cutting and lower sales volume across swine, poultry and other vaccines.

  • Net Loss of RMB22.2 Million

    Net loss was RMB22,163 thousand (US$3,267 thousand) versus RMB25,550 thousand a year earlier; operating loss narrowed to RMB20,823 thousand (US$3,069 thousand) as expenses were cut.

  • Going-Concern Doubt Disclosed

    The filing states conditions 'initially raised substantial doubt about the Company's ability to continue as a going concern,' which management says is alleviated by renewing existing short-term bank loans.

  • Full Deferred-Tax Valuation Allowance

    A valuation allowance of RMB26,609 thousand (US$3,922 thousand) was recorded against all deferred tax assets, cutting income tax benefits to RMB99 thousand (US$14 thousand) from RMB5,340 thousand.


Analysis · ZYBT · Life Sciences

Zhengye's first-half 2026 results show a shrinking business burning cash: revenue fell 18.3% to RMB50.9 million (US$7.5 million), and the company lost RMB22.2 million (US$3.3 million). Losses and cash burn 'initially raised substantial doubt about the Company's ability to continue as a going concern,' according to the filing, and management says it can address that doubt only by renewing short-term bank loans. Cash fell to RMB31.9 million (US$4.7 million) from RMB50.3 million at year-end, working capital is down to RMB5.1 million (US$0.8 million), and the company took a full RMB26.6 million (US$3.9 million) valuation allowance against its deferred tax assets — a signal it does not expect to be profitable enough to use them. The largest customer is also producing vaccines in-house, cutting its purchases from RMB12.5 million to RMB5.2 million.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZYBT was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.6M. The 52-week trading range was $0.62 to $8.01. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZYBT - Latest Insights

ZYBT
Aug 06, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.51 info
Change: -$0.670 (-31%) info
Market Cap: $44.587M info
ZYBT
Jun 04, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.830
Real-time Price: $1.51 info
Change: +$0.680 (+82%) info
Market Cap: $44.587M info
ZYBT
Apr 28, 2026, 4:55 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.9225
Real-time Price: $1.51 info
Change: +$0.5875 (+64%) info
Market Cap: $44.587M info
ZYBT
Apr 28, 2026, 4:31 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.9225
Real-time Price: $1.51 info
Change: +$0.5875 (+64%) info
Market Cap: $44.587M info
ZYBT
Mar 24, 2026, 7:16 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.820
Real-time Price: $1.51 info
Change: +$0.690 (+84%) info
Market Cap: $44.587M info